ArticleFrontiers in medicine2026
Individualized perioperative decision-making for intraoperative cell salvage in an Rh(D)-negative patient with placenta percreta: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Placenta accreta spectrum (PAS), and particularly placenta percreta, is one of the most hemorrhage-prone conditions in obstetric surgery. In Rh(D)-negative women, the conventional toolkit of patient blood management is constrained: compatible allogeneic supply is scarce, and intraoperative cell salvage (ICS) raises a specific concern about residual fetal red cell exposure and Rh alloimmunization. We report the perioperative course of a 29-year-old gravida 3, para 2 woman with O Rh(D)-negative blood, preoperative anemia (hemoglobin 86 g/L), placenta percreta with suspected bladder invasion, and intrahepatic cholestasis of pregnancy, who underwent cesarean subtotal hysterectomy at 32 weeks of gestation after multidisciplinary planning. Hemorrhage control combined intermittent abdominal aortic balloon occlusion (IABO), tranexamic acid, definitive surgical hemostasis, and timely transfusion of 7 units of cross-matched O Rh(D)-negative packed red blood cells and 600 mL of fresh frozen plasma. ICS was activated after fetal delivery and 900 mL of processed autologous blood was held in reserve; reinfusion was not undertaken after hemorrhage had been controlled through IABO, definitive surgical hemostasis, and same-type allogeneic transfusion, while hemoglobin remained ≥ 80 g/L and no additional red-cell support was considered clinically necessary. This was a case-specific intraoperative judgment rather than a predefined protocol. Postpartum anti-D immunoglobulin was not administered, and no postpartum antibody screening was performed. Although the patient was discharged on postoperative day 5 and was clinically well at 3-month follow-up, this interval was too short to evaluate delayed alloantibody formation. Therefore, her subsequent alloimmunization status and the immunohematologic safety of this management could not be determined. This report describes one context-specific decision to prepare and retain ICS blood without subsequent reinfusion. It does not establish that withholding reinfusion is safe or preferable and does not provide a generalizable strategy or threshold for other Rh(D)-negative patients with PAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.